Total Funding
53
37
Total FundingVenture - Series Unknown raised
Growth Score 53 in past quarter
-7 pts
Heat Score 37 in past quarter
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
150453
Caldan Therapeutics Ltd, a spin-out from a long-standing collaboration between Professor Trond Ulven at the University of Southern Denmark
- Trond Ulven: Director and Co-Founder
- Mark Payton: CEO
About the Company
Caldan Therapeutics Ltd is a spinout company from the University of Glasgow (UofG) and the University of Southern Denmark (SDU), developing novel therapeutics targeting modulators of free fatty acid receptors, for metabolic disease including Type 2 Diabetes (T2D) and other indications.
The spinout opportunity has arisen from a long term
collaboration between Professor Graeme Milligan (UofG) and Professor Trond Ulven (SDU).
Free fatty acid receptors have recently emerged as exciting targets for T2D, due to their involvement in multiple aspects of T2D pathophysiology. There may also be potential to explore other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.
